Houston – 26 October 2015 – The Company of SpinalCyte, LLC in an announcement released the contents of the presentation that was delivered by the SpinalCyte’s C.E.O cum the President, Pete O’Heeron.
The said presentation was given at the Middle East North Africa, in short MENA’s “Private Equity & Venture Capital Summit” on the 25th and 26th of October 2015. The summit was held at Riyadh in Saudi Arabia.
SpinalCyte, LLC is based in Taxes and develops “tissue engineering” technologies especially for re-growing the “spinal disc nucleus”. The company attempts to do so by using the “dermal fibroblasts” of humans.
BusinessWire informing about SpinalCyte, LLC writes:
“Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts”.
SpinalCyte has set its goal for developing a technology that will be capable of regenerating “a cartilage”, whereby the technology takes the help of “autologous dermal cells” that are usually “harvested from the patient”.
Ever since its beginning till date, “angel investors” have entirely supported SpinalCyte.
References:
www.businesswire.com
The said presentation was given at the Middle East North Africa, in short MENA’s “Private Equity & Venture Capital Summit” on the 25th and 26th of October 2015. The summit was held at Riyadh in Saudi Arabia.
SpinalCyte, LLC is based in Taxes and develops “tissue engineering” technologies especially for re-growing the “spinal disc nucleus”. The company attempts to do so by using the “dermal fibroblasts” of humans.
BusinessWire informing about SpinalCyte, LLC writes:
“Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts”.
SpinalCyte has set its goal for developing a technology that will be capable of regenerating “a cartilage”, whereby the technology takes the help of “autologous dermal cells” that are usually “harvested from the patient”.
Ever since its beginning till date, “angel investors” have entirely supported SpinalCyte.
References:
www.businesswire.com